共 48 条
- [41] Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a phase 2, single-arm feasibility studyCANCER RESEARCH, 2012, 72Traina, T. A.Hudis, C.Fornier, M.Lake, D.Lehman, R.Berkowitz, A. P.Rege, J.Liao, J.Cox, D.Seidman, A. D.
- [42] Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 studyLUNG CANCER, 2014, 86 (01) : 47 - 53Santoro, ArmandoHillerdal, Gunnar N.Hoeffkenc, GertFavaretto, AdolfoCarrion, Ramon PerezVisseren-Grul, CarlaAmeryckx, SophieHelsberg, KarinSoldatenkova, VictoriaBourayou, NawelSorensen, Jens B.
- [43] An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for the treatment of central nervous system progression post-radiotherapy in patients with HER2-positive metastatic breast cancer (PATRICIA)CANCER RESEARCH, 2016, 76Lin, N. U.Pegram, M. D.Lai, C.Lacasia, A.Stein, A.Yoo, B.Perez, E. A.
- [44] Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy Results of an Open Noncomparative Phase 2 Multicenter Italian Study (After-6 Protocol 2)INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (04) : 615 - 619Gadducci, AngioloKatsaros, DionyssiosZola, PaoloScambia, GiovanniBallardini, MichelaPasquini, EnzoFertonani, CarloMaggi, LorenzoPecorelli, SergioConte, Pier Franco
- [45] Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI117E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts) with asymptomatic or Inter mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Hussain, MahaMiller, KurtRybicka, IlonaBruns, Rolf
- [46] An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for treatment of central nervous system (CNS) progression post-radiotherapy in patients (pts) with HER2-positive metastatic breast cancer (MBC): PATRICIA.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Lin, Nancy U.Lai, CatherineLacasia, AndreaStein, AlishaYoo, BonginFung, AnitaPegram, Mark D.
- [47] Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)BMJ OPEN, 2022, 12 (06):Lau, Sai Pingvan 't Land, Freek R.van der Burg, Sjoerd H.Homs, Marjolein Y., VLolkema, Martijn P.Aerts, Joachim G. J., Vvan Eijck, Casper H. J.
- [48] Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RI) in patients (pts) with HER2-positive metastatic breast cancer (MBC).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Lin, Nancy U.Stein, AlishaNicholas, AlanFung, Anita M.Kumthekar, PriyaIbrahim, Nuhad K.Pegram, Mark D.